Comment on: Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement

Journal Article Accepted manuscript Comment on: Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement Get access Ciro Manzo, Ciro Manzo Internal and Geriatric Medicine Department, Rheumatology Outpatient clinic, Health District no. 59, Naples, Italy Correspondence to: Ciro Manzo, Poliambulatorio "Mariano Lauro" via dei Pini 1, 80065, Sant'Agnello (Naples, Italy), E-mail: manzoreumatologo@libero.it https://orcid.org/0000-0002-5348-3814 Search for other works by this author on: Oxford Academic PubMed Google Scholar Maria Natale, Maria Natale Internal and Geriatric Medicine Department, Rheumatology Outpatient clinic, Health District no. 59, Naples, Italy Search for other works by this author on: Oxford Academic PubMed Google Scholar Marco Isetta, Marco Isetta Library and Knowledge Services, Central and North West London NHS Foundation Trust, London, UK Search for other works by this author on: Oxford Academic PubMed Google Scholar Alberto Castagna Alberto Castagna Primary Care Department, Azienda Sanitaria Provinciale Catanzaro, Catanzaro, Italy https://orcid.org/0000-0002-6786-4116 Search for other works by this author on: Oxford Academic PubMed Google Scholar Rheumatology, keae259, https://doi.org/10.1093/rheumatology/keae259 Published: 08 May 2024 Article history Received: 13 March 2024 Accepted: 27 March 2024 Published: 08 May 2024